Bio-Techne Management
Management criteria checks 2/4
Bio-Techne's CEO is Kim Kelderman, appointed in Feb 2024, has a tenure of less than a year. total yearly compensation is $6.85M, comprised of 11.1% salary and 88.9% bonuses, including company stock and options. directly owns 0.025% of the company’s shares, worth $2.85M. The average tenure of the management team and the board of directors is 1.3 years and 7.9 years respectively.
Key information
Kim Kelderman
Chief executive officer
US$6.9m
Total compensation
| CEO salary percentage | 11.1% |
| CEO tenure | less than a year |
| CEO ownership | 0.02% |
| Management average tenure | 1.3yrs |
| Board average tenure | 7.9yrs |
Recent management updates
Recent updates
Why We're Not Concerned About Bio-Techne Corporation's (NASDAQ:TECH) Share Price
Dec 15
There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings
Nov 06Is Bio-Techne (NASDAQ:TECH) A Risky Investment?
Sep 26Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching
Sep 11Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings
Aug 24When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jun 09Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up
May 21These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Apr 30Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
Apr 15Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Bio-Techne releases new AVV viral titer assays
Oct 11Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$151m |
| Jun 30 2024 | US$7m | US$760k | US$168m |
| Mar 31 2024 | n/a | n/a | US$203m |
| Dec 31 2023 | n/a | n/a | US$224m |
| Sep 30 2023 | n/a | n/a | US$247m |
| Jun 30 2023 | US$3m | US$590k | US$285m |
| Mar 31 2023 | n/a | n/a | US$271m |
| Dec 31 2022 | n/a | n/a | US$262m |
| Sep 30 2022 | n/a | n/a | US$292m |
| Jun 30 2022 | US$3m | US$562k | US$272m |
| Mar 31 2022 | n/a | n/a | US$225m |
| Dec 31 2021 | n/a | n/a | US$210m |
| Sep 30 2021 | n/a | n/a | US$177m |
| Jun 30 2021 | US$4m | US$530k | US$140m |
| Mar 31 2021 | n/a | n/a | US$184m |
| Dec 31 2020 | n/a | n/a | US$175m |
| Sep 30 2020 | n/a | n/a | US$248m |
| Jun 30 2020 | US$2m | US$500k | US$229m |
| Mar 31 2020 | n/a | n/a | US$187m |
| Dec 31 2019 | n/a | n/a | US$195m |
| Sep 30 2019 | n/a | n/a | US$93m |
| Jun 30 2019 | US$2m | US$452k | US$96m |
| Mar 31 2019 | n/a | n/a | US$121m |
| Dec 31 2018 | n/a | n/a | US$96m |
| Sep 30 2018 | n/a | n/a | US$128m |
| Jun 30 2018 | US$2m | US$73k | US$126m |
Compensation vs Market: Kim's total compensation ($USD6.85M) is below average for companies of similar size in the US market ($USD12.85M).
Compensation vs Earnings: Kim's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Kim Kelderman (57 yo)
less than a year
Tenure
US$6,852,495
Compensation
Mr. Kim Kelderman serves as Director of SLMP, LLC since November 2021. He serves as President of the Diagnostics and Genomics Segment at Bio-Techne. He served as Chief operating Officer at Bio-Techne Corpo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$6.85m | 0.025% $ 2.8m | |
| Executive VP of Finance & CFO | 10.7yrs | US$5.20m | 0.067% $ 7.8m | |
| Senior VP | 1.8yrs | US$1.46m | 0.0011% $ 123.0k | |
| President of Protein Sciences Segment | 2.9yrs | US$3.65m | 0.0070% $ 808.8k | |
| President of Diagnostics & Genomics | less than a year | US$2.27m | no data | |
| VP & CTO | less than a year | no data | no data | |
| Senior Director of Investor Relations & Corporate Development | no data | no data | no data | |
| Vice President of Sales and Marketing | no data | no data | no data | |
| Senior Vice President of Strategy & Corporate Development | less than a year | no data | no data | |
| Senior VP & Chief Human Resources Officer | less than a year | no data | no data | |
| Managing Director | 8.4yrs | no data | no data | |
| Senior Vice President of Analytical Solutions Division | 1.9yrs | no data | no data |
1.3yrs
Average Tenure
55yo
Average Age
Experienced Management: TECH's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.9yrs | US$6.85m | 0.025% $ 2.8m | |
| Independent Chairman of the Board | 21.9yrs | US$410.46k | 0.028% $ 3.3m | |
| Independent Director | 15.6yrs | US$300.46k | 0.030% $ 3.5m | |
| Independent Director | 7.9yrs | US$275.46k | 0.0087% $ 1.0m | |
| Independent Director | 14.6yrs | US$290.46k | 0.028% $ 3.3m | |
| Independent Director | 4.4yrs | US$291.50k | 0.0045% $ 521.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.9yrs | US$275.46k | 0.0087% $ 1.0m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | US$113.73k | 0.0014% $ 156.7k | |
| Independent Director | 5.5yrs | US$275.46k | 0.0059% $ 682.3k |
7.9yrs
Average Tenure
63yo
Average Age
Experienced Board: TECH's board of directors are considered experienced (7.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 19:02 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bio-Techne Corporation is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| James Francis Mainwaring | Atlantic Equities LLP |
| Catherine Ramsey Schulte | Baird |